ARETEON PTE LTD亚绿基公司

We create possibilities in veterinary therapeutics

INVESTMENT/BUSINESS OPPORTUNITY

PATENTED, NON-BACTERIAL

RESISTANCEANTIMICROBIAL AND ANTI-FUNGAL DRUG

© Areteon Pte Ltd

2ANTIMICROBIAL DRUG RESISTANCE

1. The first anti-microbial drug was discovered in 1929 : Penicillin

2. The last true antibiotic was discovered in 1960s

3. Today, there are only 7 antibiotic scaffolds. All the so-called recent “discoveries” are based on manipulating the existing scaffolds. This encourages multi-drug resistance very rapidly

© Areteon Pte Ltd

3ANTIMICROBIAL DRUG RESISTANCE

Antimicrobial drugs need to enter the bacterium to

be able to kill the bacterium or stop it from

replicating

Mode of action #1

© Areteon Pte Ltd

4ANTIMICROBIAL DRUG RESISTANCE

Mode of action #2

Antimicrobial drugs need to breakthrough the

biofilm that protects the bacteria

© Areteon Pte Ltd

5DMDC: NOVEL MODE OF ACTIONPatent pending; PCT/SG2014/000053

Poly-cationic chitosan-based polymer

Quaternary ammonium (positively charged)Glucosamine moiety

PEG

© Areteon Pte Ltd

6DMDC: NOVEL MODE OF ACTIONPatent pending; PCT/SG2014/000053

RNA

DNA

Cell wall(negatively charged)

Staphylococcus aureus

DMDC(positively charged)

Electrostatic bonding

© Areteon Pte Ltd

7DMDC: NOVEL MODE OF ACTIONPatent pending; PCT/SG2014/000053

Staphylococcus aureus

DMDC(positively charged)

Bacterial lysis = bactericidal

© Areteon Pte Ltd

8DMDC: NOVEL MODE OF ACTIONPatent pending; PCT/SG2014/000053

Does not need to penetrate the bacterium

Cannot be neutralized by the enzymes in the

bacterium

No risk of bacterial resistance to DMDC

© Areteon Pte Ltd

9DMDC: NOVEL MODE OF ACTIONPatent pending; PCT/SG2014/000053

Treatment by

DMDC

Electron-microscopy of destruction of S. aureus

Perforation of cell wall = Death of bacteria

© Areteon Pte Ltd

10DMDC: TRIALS CONDUCTEDPatent pending; PCT/SG2014/000053

Efficacy: 4% shampoo formulation

Observation parameters

Treatment periodDay 0 Day 7 Day 14 Day 21

Pruritus1

OwnerClinician

4.334.00

3.333.33

3.002.67

2.332.33

Bacterial Load2

PapulesPustulesSkin flakes

2.282.562.00

1.672.111.50

1.441.721.00

0.560.940.00

Symptoms 3

PapulesPustulesSkin flakesScabs/Dandruff

3.673.002.503.50

3.672.672.502.50

3.002.331.502.50

2.332.331.502.00

Fur Coat4

ShineOdourFur loss

4.003.674.00

3.672.674.00

3.002.334.00

2.331.673.00

© Areteon Pte Ltd

11DMDC: 3X Minimum Inhibitory Concentration Trials Conducted for “OralGarde” Veterinary Mouth-Spray Patent pending; PCT/SG2014/000053

S. aureus (μg/mL) E. coli (μg/mL) P. aeruginosa (μg/mL) MRSA (μg/mL)

12.5 25 25 15

12.5 25 25 15

12.5 25 25 15

© Areteon Pte Ltd

12DMDC: TRIALS CONDUCTEDPatent pending; PCT/SG2014/000053

Safety: Acute oral toxicity (OECD guideline 423)

1. LD50 > 2,000 mg/kg of body weight.

2. All rats appeared normal thereafter till euthanized. No untoward clinical signs were observed during this period.

3. All rats did not have significant lesions observed on gross pathology.

© Areteon Pte Ltd

13DMDC: MILESTONES ACHIEVEDPatent pending; PCT/SG2014/000053

S$600,000 seed funding by business

angel in May 2012

Successful completion of preliminary

trials on potency,

efficacy and safety on Sep

2013

Optimization of chemical synthesis at

mass - production scale with

significantly improved potency.

Sales launch in Q1 2017 new Topical

Products formulated with DMDC

significantly improved potency and raise

capital for expansion.

S$725,000 Singapore

government funding between Jan 2013 and Dec

2015

© Areteon Pte Ltd

14

ARETEON PTE LTD亚绿基公司

We create possibilities in veterinary therapeutics

ARETEON PTE LTD19 Tai Seng Avenue,

#06-19 Home-Fix Building,

Singapore 534054

THANK YOU !